Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Potent Selectivity: Nimbus Entrusts IRAK4 Program To Genentech

This article was originally published in Scrip

Executive Summary

Even the most ambitious early-stage biopharma has to prioritize which programs it will take on itself and which might advance more quickly and fully in the hands of a more-experienced and deeper-pocketed partner. Having used its computational chemistry platform to generate IRAK4 inhibitors with potential in autoimmune disease and B-cell lymphomas, Nimbus Therapeutics has licensed global rights to that program to Genentech Inc.

You may also be interested in...



Deal Watch: Lilly Finds New Partners For Genetic Disorders, Protein Degradation

Pharma’s latest partnerships focus on Duchenne muscular dystrophy with Precision Biosciences, protein degradation with Seed. Bristol and Schrodinger team in computational drug discovery.

Alnylam Turns To Value-Based Pricing Again For Oxlumo

As with its first two approved RNAi therapies, Alnylam will negotiate value-based agreements with payers, but for Oxlumo, approved in pediatric patients, it will offer a patient need adjustment.

Merck & Co. Buys Out OncoImmune For Phase III COVID-19 Therapy

Deal snapshot: For $425m up front, the pharma obtains a Phase III recombination fusion protein that shows ability to improve hospitalized patients’ clinical status and reduce risk of death.

Topics

Related Companies

UsernamePublicRestriction

Register

LL018264

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel